Nestle looks to develop new products to serve users of weight-loss drugs
VEVEY, Switzerland, August 17 (Reuters) - Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy. The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages.
Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓
VEVEY, Switzerland, August 17 (Reuters) - Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy. The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages. Nestle believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss. Chief Technology Officer Stefan Palzer told Reuters that Nestle was using AI and other technology to analyse clinical research, identify nutrient combinations and develop products tailored to GLP-1 users.
Read the full report at Investing.com · Stock Market ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- VEVEY, Switzerland, August 17 (Reuters) - Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy. The rapid adoption of drugs made by Novo Nordisk and Eli Lilly has fuelled investor concerns that appetite-suppressing medicines could permanently reduce demand for packaged foods, snacks and beverages.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 8m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Nestle looks to develop new products to serve users of weight-loss drugs
Sources1TypeCoverageInvesting.com · Stock Market